Safety and efficacy of topical infliximab in a mouse model of ocular surface scarring

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 3, 2013, Pages 1680-1688

  Ferrari, Giulio ^a   Bignami, Fabio ^a   Giacomini, Chiara ^a   Franchini, Stefano ^a   Rama, Paolo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL TEAR; CD45 ANTIGEN; INFLIXIMAB; INTERLEUKIN 1BETA; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUSTIC BURN; CELL INFILTRATION; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; CORNEA OPACITY; CORNEA PERFORATION; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; FEMALE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPHANGIOGENESIS; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; OCULAR FIBROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SCAR FORMATION; SCORING SYSTEM; SINGLE DRUG DOSE; SLIT LAMP; WOUND HEALING;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; BURNS, CHEMICAL; CONJUNCTIVA; CORNEA; CORNEAL NEOVASCULARIZATION; EYE BURNS; EYELIDS; FEMALE; FIBROSIS; GOBLET CELLS; INTERLEUKIN-1BETA; LEUKOCYTES; LYMPHANGIOGENESIS; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; RANDOM ALLOCATION; TEARS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84874611029     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10782     Document Type: Article

References (25)

1. Xiang H, Stallones L, Chen G, Smith GA. Work-related eye injuries treated in hospital emergency departments in the US. Am J Ind Med. 2005;48:57-62.
2. Morgan SJ. Chemical burns of the eye: causes and management. Br J Ophthalmol. 1987;71:854-857.
3. Kuckelkorn R, Schrage N, Keller G, Redbrake C. Emergency treatment of chemical and thermal eye burns. Acta Ophthalmol Scand. 2002;80:4-10.
4. Kitano A, Saika S, Yamanaka O, et al. Emodin suppression of ocular surface inflammatory reaction. Invest Ophthalmol Vis Sci. 2007;48:5013-5022.
5. Elder MJ, Dart J., Lightman S. Conjunctival fibrosis in ocular cicatricial pemphigoid-the role of cytokines. Exp Eye Res. 1997;65:165-176.
6. Saika S, Ikeda K, Yamanaka O, et al. Loss of tumor necrosis factor alpha potentiates transforming growth factor betamediated pathogenic tissue response during wound healing. Am J Pathol. 2006;168:1848-1860.
7. Mohan RR, Mohan RR, Kim WJ, Wilson SE. Modulation of TNFalpha-induced apoptosis in corneal fibroblasts by transcription factor NF-kappaB. Invest Ophthalmol Vis Sci. 2000;41:1327-1336.
8. Satici A, Guzey M, Dogan Z, Kilic A. Relationship between Tear TNF-alpha, TGF-beta1, and EGF levels and severity of conjunctival cicatrization in patients with inactive trachoma. Ophthalmic Res. 2003;35:301-305.
9. Sakimoto T, Yamada A, Sawa M. Release of soluble tumor necrosis factor receptor 1 from corneal epithelium by TNFalpha-converting enzyme-dependent ectodomain shedding. Invest Ophthalmol Vis Sci. 2009;50:4618-4621.
10. Markomichelakis NN, Theodossiadis PG, Sfikakis PP. Regression of neovascular age-related macular degeneration following infliximab therapy. Am J Ophthalmol. 2005;139:537-540.
11. Lu P, Li L, Liu G, et al. Critical role of TNF-alpha-induced macrophage VEGF and iNOS production in the experimental corneal neovascularization. Invest Ophthalmol Vis Sci. 2012; 53:3516-3526.
12. Streit M, Beleznay Z, Braathen LR. Topical application of the tumour necrosis factor-alpha antibody infliximab improves healing of chronic wounds. Int Wound J. 2006;3:171-179.
13. Yoeruek E, Ziemssen F, Henke-Fahle S, et al. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol. 2008;86:322-328.
14. Barabino S, Shen L, Chen L, Rashid S, Rolando M, Dana MR. The controlled-environment chamber: a new mouse model of dry eye. Invest Ophthalmol Vis Sci. 2005;46:2766-2771.
15. Dahab GM, Kheriza MM, El-Beltagi HM, Fouda AM, El-Din OA. Digital quantification of fibrosis in liver biopsy sections: description of a new method by Photoshop software. J Gastroenterol Hepatol. 2004;19:78-85.
16. Williams KA, Esterman AJ, Bartlett C, Holland H, Hornsby NB, Coster DJ. How effective is penetrating corneal transplantation? Factors influencing long-term outcome in multivariate analysis. Transplantation. 2006;81:896-901.
17. Ottiger M, Thiel MA, Feige U, Lichtlen P, Urech DM. Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer. Invest Ophthalmol Vis Sci. 2009;50: 779-786.
18. Cursiefen C, Chen L, Dana MR, Streilein JW. Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology. Cornea. 2003;22:273-281.
19. Yamagami S, Dana MR. The critical role of lymph nodes in corneal alloimmunization and graft rejection. Invest Ophthalmol Vis Sci. 2001;42:1293-1298.
20. Saw VP, Dart RJ, Galatowicz G, Daniels JT, Dart J., Calder VL. Tumor necrosis factor-alpha in ocular mucous membrane pemphigoid and its effect on conjunctival fibroblasts. Invest Ophthalmol Vis Sci. 2009;50:5310-5317.
21. Saw VP, Schmidt E, Offiah I, et al. Profibrotic phenotype of conjunctival fibroblasts from mucous membrane pemphigoid. Am J Pathol. 2011;178:187-197.
22. Sotozono C, He J, Matsumoto Y, Kita M, Imanishi J, Kinoshita S. Cytokine expression in the alkali-burned cornea. Curr Eye Res. 1997;16:670-676.
23. Chan LS. Ocular and oral mucous membrane pemphigoid (cicatricial pemphigoid). Clin Dermatol. 2012;30:34-37.
24. Dart J. Cicatricial pemphigoid and dry eye. Semin Ophthalmol. 2005;20:95-100.
25. Nomoto H, Shiraga F, Kuno N, et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci. 2009;50: 4807-4813.